Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Washingtonpost

Published November 19, 2026 · Updated November 20, 2026

Health Brief: Drugmakers see promise in psychedelics - The Washington Post

Read the full story at Washingtonpost

Otsuka has spent years building a portfolio of psychedelic -derived treatments, including a potential PTSD drug now in Phase 3 trials; I talk with the.

Surfaced by 3 Google Alerts

  • Psychedelics
  • Magic mushrooms
  • Psychedelic biotech